Berwyn, Pennsylvania--(Newsfile Corp. - May 6, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the U.S. Patent and Trademark Office (USPTO) granted the Company's patent (US 16/504,813) for a method of treating tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy by administering ANVS401.
This is the Company's third issued patent in its chronic neurodegenerative patent family. Previously, the USPTO requested the Company to split its original neurodegenerative patent application into a number of patents, each covering individual diseases targeted by ANVS401. The two previously issued patents cover AD and alpha-synucleopathies, such as PD; the new patent covers tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy. This latest patent was issued because ANVS401 lowers the levels of tau and phospho-tau.
From the acute patent family, which provides intellectual property protection through 2036, Annovis Bio has been issued two patents: one covering Europe and one covering Japan. As with its chronic neurodegenerative patent family, in the US, the Company is targeting patents in each individual acute disease and has already filed divisional applications for treatment of traumatic brain injury, stroke, and spinal cord injury by administering ANVS405.
"We are thrilled to further expand our intellectual property protections," said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer. "Our unique approach to treating neurodegeneration targets the same toxic cascade leading to nerve cell death in chronic as well as acute brain injuries. The same mechanism starts out with high levels of neurotoxic proteins that leads to impairment in axonal transport, inflammation and to nerve cells dying. With additional patent applications pending, we look forward to providing further updates as new allowances are granted."
ANVS401 and ANVS405 can work in chronic and acute indications because nerve cells die by the same mechanism in these diseases. ANVS401 and ANVS405 stop the toxic cascade leading to nerve cell death. Capitalizing on that knowledge, Annovis Bio is conducting two Phase 2 studies to show in both AD and PD patient populations that what was demonstrated in animals can be reproduced in humans and that ANVS401 protects the nerve cells from dying, and by doing so, preserves the associated function.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83123
